Rocket Pharma Gets Regenerative Medicine Advanced Therapy Designation for RP-L301
By Chris Wack
Rocket Pharmaceuticals said Tuesday that the U.S. Food and Drug Administration has granted a regenerative medicine advanced therapy designation to RP-L301, the company's investigational lentiviral-based gene therapy for pyruvate kinase deficiency.
The Cranbury, N.J.-based late-stage biotechnology company said RMAT designation was granted based on RP-L301's robust safety and efficacy data from an ongoing Phase 1 clinical trial, and its potential to cure a life-threatening disease for which no curative therapies currently exist.
The RMAT designation will provide the benefits of added FDA guidance and expedited review throughout the RP-L301 program's development. RP-L301 has also received the FDA's fast track and orphan drug designations.
Rocket Pharma said RP-L301's safety profile appears highly favorable, with no RP-L301-related serious adverse events in either of the adult patients.
The program's first pediatric patient results suggest efficacy similar to the adult cohort with an initial greater than a five-point increase in hemoglobin. The infusion was well-tolerated, and no RP-L301-related serious adverse events or red blood cell transfusion requirements followed engraftment.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
May 23, 2023 07:36 ET (11:36 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
5 Undervalued Stocks That Crushed Earnings for Q1 2024
-
What Does Nvidia’s Stock Split Mean for Investors?
-
After Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Target Stock a Buy, Sell, or Fairly Valued?
-
Obesity Drug Stocks: Where to Invest Now
-
How to Invest Like Warren Buffett
-
DuPont Split Gives Investors Better Choices
-
2 Wide-Moat Stocks to Consider
-
Live Nation: Breakup Sought by Department of Justice Probably Wouldn’t Affect Fair Value Much
-
After Earnings, Is Applied Materials Stock a Buy, Sell, or Fairly Valued?
-
The Best Energy Stocks to Buy